Bayer to acquire Asklepios BioPharmaceutical for up to $4bn

This article was originally published here

As per terms of the deal, Asklepios will secure an upfront consideration of $2bn and potential success-based milestone payments of up to $2bn from Bayer. Based in North

The post Bayer to acquire Asklepios BioPharmaceutical for up to $4bn appeared first on Pharmaceutical Business review.